The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Bioeng. Biotechnol.
Sec. Nanobiotechnology
Volume 12 - 2024 |
doi: 10.3389/fbioe.2024.1444107
This article is part of the Research Topic Research on Nanomaterials in Tumor Diagnosis and Therapy View all 7 articles
DDS-type near-infrared light absorber enables deeper lesion treatment in laser photothermal therapy while avoiding damage to surrounding organs
Provisionally accepted- 1 The University of Tokyo, Bunkyo, Tōkyō, Japan
- 2 Department of Surgery, National Defense Medical College (Japan), Tokorozawa, Saitama, Japan
- 3 Department of Pediatric Surgery, Graduate School of Medicine, Nagoya University, Nagoya, Aichi, Japan
- 4 Department of Physiology, National Defense Medical College (Japan), Tokorozawa, Japan
- 5 Technology Research Laboratory, Shimadzu Corporation, Kyoto, Kyōto, Japan
- 6 Department of applied chemistry and biotechnology, faculty of engineering, Okayama University, Okayama, Okayama, Japan
The efficacy of drug delivery system (DDS)-type near-infrared (NIR) absorbing agents in enhancing laser photothermal therapy is widely acknowledged. Despite the acknowledged efficacy, the therapeutic advantages of photothermal therapy using DDS-type NIR-absorbing agents over simple photothermal therapy without such agents have not been fully elucidated. This study was designed to investigate two primary objectives: firstly, the ability of DDS-type NIR-absorbing agents to induce cell death at greater depths within tumors, and secondly, their capacity to minimize collateral damage to adjacent healthy organs. To investigate these objectives, we employed a combination of indocyanine green lactosome-a DDS-type NIR-absorbing agent-and a precision-controlled laser hyperthermia system. An orthotopic neuroblastoma tumor model was used to closely simulate clinical conditions. The findings revealed that photothermal therapy using the DDS-type NIRabsorbing agent not only facilitates deeper penetration of cell death within tumors but also significantly mitigates thermal damage to surrounding healthy tissues, when compared to simple phototherapy without the agent. Furthermore, the combined treatment significantly prolonged the survival periods of the animals involved. This study is the first to analyze these therapeutic efficacies using quantitative data from an orthotopic tumor animal model and substantiated the potential of DDS-type NIR-absorbing agents to deepen the therapeutic impact of photothermal therapy while safeguarding vital organs, thereby enhancing overall treatment outcomes.
Keywords: TT: validation, supervision. HU: conceptualization, Validation, supervision. YM: conceptualization, Funding acquisition, project administration, methodology, supervision
Received: 05 Jun 2024; Accepted: 30 Jul 2024.
Copyright: © 2024 Takahashi, Fujishiro, Nomura, Harada, Hinoki, Arake, Ozeki, Hara, Satoh, Tainaka, Uchida and MORIMOTO. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Masataka Takahashi, The University of Tokyo, Bunkyo, 113-8654, Tōkyō, Japan
YUJI MORIMOTO, Department of Physiology, National Defense Medical College (Japan), Tokorozawa, Japan
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.